SYSTEMIC SCLEROSIS

This is an early-stage safety study testing a new two-part cell therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to other treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a specifi…

This study is testing whether an investigational drug called MT-0551 can reduce skin thickening in people with systemic sclerosis, a rare autoimmune disease that causes hardening of the skin and internal organs. The trial will compare MT-0551 against a placebo in 80 patients over…

This study is testing whether a drug called baricitinib is better than the standard treatment (cyclophosphamide) at reducing skin thickening and improving symptoms in people with early, severe systemic sclerosis. It involves 60 adults who will take the assigned medication for 48 …

This early-stage study is testing the safety and initial effects of a new cell therapy called RD06-04 for people with active, severe autoimmune diseases. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove certain harmful immune cells. T…

This study is testing whether a medication called anifrolumab, given as a weekly injection, can safely help control the symptoms and slow the progression of systemic sclerosis (scleroderma). It will involve about 314 adults with a recent diagnosis of the disease. Participants wil…

This is an early-stage study testing a new personalized cell therapy called KITE-363 for people with severe autoimmune diseases that haven't improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells, which …

This study is testing a new type of cell therapy for people with severe lupus or scleroderma that hasn't responded to standard treatments. Doctors are giving patients a single infusion of specially engineered immune cells designed to target and reduce harmful B cells. The main go…

This early-stage study is testing a new personalized cell therapy called KYV-101 for adults with active, diffuse systemic sclerosis (scleroderma). The therapy involves modifying a patient's own immune cells to target and remove certain B-cells thought to drive the disease. The ma…

This study is testing different ways to help people with inflammatory arthritis who face life challenges like unstable housing or transportation issues that make it hard to get medical care. It compares three levels of support: a simple resource list, help from a community specia…

This study is checking if the Shingrix shingles vaccine is safe and works well for people with autoimmune rheumatic diseases like lupus or rheumatoid arthritis. These patients are at high risk for shingles but are often on medications that weaken the immune system. Researchers ar…

This small pilot study is testing whether a fecal microbiota transplant (FMT), which transfers healthy gut bacteria from a donor, is safe and can help reduce chronic diarrhea in people with systemic sclerosis (scleroderma). Twenty participants will be randomly assigned to receive…

This study aims to see if a computer program (AI) can analyze old chest CT scans to predict which patients with scleroderma-related lung scarring will get worse. It will look at about 1,000 patients' past scans and health records to find patterns. The goal is to help doctors iden…